NECTIN2: A Potential Drug Target and Biomarker (G5819)

Target Name: NECTIN2

NCBI ID: G5819

NECTIN2

NECTIN2: A Potential Drug Target and Biomarker

Introduction

Nucleotide-binding oligomerization (NBO) proteins, also known as nucleotide-binding proteins or nucleotide-binding oligomerization proteins (NOPs), are a family of proteins that play a crucial role in various cellular processes, including DNA replication, transcription, and splicing. . NECTIN2, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

NECTIN2: Structure and Function

NECTIN2 is a 21-kDa protein that consists of a unique nucleotide-binding oligomerization domain and a T-loop domain. The NECTIN2 protein was first identified using bioinformatics analysis of human transcripts using the U12 cell nuclear extract as the source. NECTIN2 has been shown to have a highly conserved amino acid sequence, with a calculated pI of 9.97.

NECTIN2 has been shown to play a role in various cellular processes, including cell growth, differentiation, and survival. For example, NECTIN2 has been shown to be involved in the regulation of cell cycle progression, where it promotes the G1/S transition and inhibits the G0/G1 transition. Additionally, NECTIN2 has been shown to play a role in the regulation of cell survival, where it has been shown to promote cell survival and inhibit cell death.

Mutational studies have identified several potential drug targets in NECTIN2. For example, missense mutations in the NECTIN2 gene have been shown to result in altered protein stability and to disrupt its functions. In addition, gain-of-function mutations have been shown to result in over-expression of NECTIN2 and to enhance its effects, suggesting that NECTIN2 may be a promising drug target.

NECTIN2: Potential Therapeutic Applications

NECTIN2 has been shown to have a promising therapeutic potential in various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

NECTIN2 has been shown to be a potential drug target for cancer, where it has been shown to promote the growth and survival of cancer cells. In addition, NECTIN2 has been shown to interact with several anti-cancer drugs, including taxanes, vinca alkaloids, and iridium-based chemotherapy drugs, and to enhance their efficacy.

NECTIN2 has also been shown to be a potential drug target for neurodegenerative diseases, where it has been shown to contribute to the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, NECTIN2 has has been shown to interact with several neurodegenerative drugs, including tau-targeting agents, and to enhance their efficacy.

NECTIN2 has also been shown to be a potential drug target for autoimmune diseases, where it has been shown to contribute to the development and progression of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis. In addition, NECTIN2 has been shown to interact with several autoimmune drugs, including corticosteroids and immunomodulatory drugs, and to enhance their efficacy.

Conclusion

NECTIN2 is a unique and promising protein that has been shown to play a role in various cellular processes and has been identified as a potential drug target and biomarker in various diseases. Its highly conserved amino acid sequence, together with its known functions, make it an attractive target for further study and development. Further studies are needed to fully understand the role of NECTIN2 in

Protein Name: Nectin Cell Adhesion Molecule 2

Functions: Modulator of T-cell signaling. Can be either a costimulator of T-cell function, or a coinhibitor, depending on the receptor it binds to. Upon binding to CD226, stimulates T-cell proliferation and cytokine production, including that of IL2, IL5, IL10, IL13, and IFNG. Upon interaction with PVRIG, inhibits T-cell proliferation. These interactions are competitive (PubMed:26755705). Probable cell adhesion protein (PubMed:9657005)

The "NECTIN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NECTIN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets